Synaptogenix, Inc.
SNPX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | -0.02 | 0.00 |
| FCF Yield | -7.19% | -6.10% | -59.66% | -27.28% |
| EV / EBITDA | -8.43 | 0.89 | -29.73 | 6.14 |
| Quality | ||||
| ROIC | -10.51% | -16.12% | -7.07% | -13.03% |
| Gross Margin | 0.00% | 100.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.30 | 0.04 | -5.19 | 0.21 |
| Growth | ||||
| Revenue 3-Year CAGR | 210,900.52% | 210,900.52% | 175,686.93% | 175,686.93% |
| Free Cash Flow Growth | -59.47% | 62.56% | -71.30% | -13.27% |
| Safety | ||||
| Net Debt / EBITDA | 0.80 | 6.15 | -38.41 | 8.11 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -9,957.65 | -10,513.93 |